| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Lab operator Quest Diagnostics said on Wednesday it will launch a test for H5N1 bird flu at the end of October after the U.S. Centers for Disease Control and Prevention (CDC) gave it contracts to support testing for two emerging infectious diseases, including the Oropouche virus. WHY IT'S IMPORTANT: The spread of bird flu among dairy herds and infections of 27 people this year have alarmed some public health experts.
Laboratory operator Quest Diagnostics beat Wall Street estimates for third-quarter profit and revenue on Tuesday, helped by robust demand for its diagnostic tests. Demand for diagnostic checkups has grown in recent quarters as more people, especially older adults, caught up on surgeries deferred during the pandemic.
Quest Diagnostics has launched a self-collection option for testing for vaginitis and similar genital tract infections such as chlamydia, gonorrhea, trichomoniasis and Mycoplasma genitalium. The test uses Hologic's FDA-cleared Aptima Multi-test swab for patient-collected vaginal specimens and can be used by patients to self-collect specimens in Quest patient service centers or in traditional clinical settings like a doctor's office.
Quest Diagnostics has completed its purchase of select laboratory assets from Columbus-based OhioHealth. The two parties signed an agreement for the assets in early July, with financial terms from the transaction not shared. The purchase aims to expand access to cost-effective laboratory services in Ohio.
Quest Diagnostics has announced seven acquisitions this year, including its recent purchase of select lab assets from Minneapolis-based Allina Health. Slated to close later this year are deals with OhioHealth in Columbus and University Hospitals in Cleveland. "In order to grow our business, we want to be able to do more work with hospitals that are doing outpatient or outreach lab tests ordered by independent physicians outside of their facility,” said Jim Davis, president and CEO of Quest Diagnostics.